Traders should prepare for potential volatility on May 6 when Q1 2026 results are released, especially given the weak prior quarter. Monitor guidance and cash burn trends in HAE pipeline updates.
Price Chart
Executive Summary
BioCryst Pharmaceuticals announced it will report Q1 2026 financial results on May 6, 2026, but provided no actual results in this press release. The prior quarter (Q4 2025) missed EPS consensus by 91%, signaling weak performance. This filing is administrative, not a results release.
Key Financial Metrics
Key Facts
- Company to report Q1 2026 results on May 6, 2026
- No financial results disclosed in this release
- Q4 2025 EPS was $0.01 vs. $0.11 consensus — 91.1% miss
- Q4 2025 revenue was $151.7M, in line with estimates
- Conference call scheduled for May 6, 2026 at 8:30 a.m. ET
Financial Impact
No financials reported; prior quarter missed EPS by 91%
Risk Factors
- Continued weak earnings performance could pressure stock
- Lack of disclosed financials in this release limits immediate trading insight
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274291 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.17 (−9.92%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.17 (−14.45%) |
Jun 12, 2026 16w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.17 (−9.82%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.17 (−6.09%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.17 (−6.52%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.17 (−14.90%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.17 (−7.47%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.17 (−11.20%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.17 (−8.61%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.17 (−13.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access